Metabolism of Methylphenidate and Enalapril Based on CES1 Genotype

Bispebjerg Hospital

Status and phase: Completed; Phase 4

Conditions: CES1 Activity; Carboxylesterase 1 (CES1) Genotype

Treatments: Drug: Methylphenidate; Drug: Enalapril

Study type: Interventional

Funder types: Other

Identifiers

NCT02135263

INDICES-WP2

Details and patient eligibility

About

The purpose of this study is to determine whether differences in the gene coding for the liver enzyme carboxylesterase 1 (CES1) means differences in the metabolism of two CES1 dependent drugs, enalapril and methylphenidate.

Enrollment: 44 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• > 18 years old
• Caucasian

Exclusion criteria

• Chronic disease (except hay fever and eczema)
• Pregnancy
• Smoking
• High level of alcohol consumption (> 21 units per week for men and 14 for women)
• Known allergy towards methylphenidate and enalapril
• Permanent use of medication (contraception ok)

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

44 participants in 2 patient groups

Methylphenidate

Experimental group

Treatment:

Drug: Methylphenidate

Enalapril

Experimental group

Treatment:

Drug: Enalapril